ProFibrix
Innovative products for the hemostasis and regenerative medicine markets.
Launch date
Employees
Market cap
-
Enterprise valuation
€218m (Public information from Aug 2013)
Seattle Washington (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$11.0m | Series A | ||
$11.4m | Series B | ||
$10.6m | Series B | ||
$240m Valuation: $240m | Acquisition | ||
Total Funding | €30.0m |